Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine or doxycycline for endothelial glycocalyx protection during cardiac surgery with cardiopulmonary bypass
ACTRN12619000621112Phase 4Recruiting
- Sponsor
- Institute for Respiratory Health
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lidocaine and doxycycline in coronary arteriosclerosis, Cardiac valve disease (VHD) and aortopathy (3 arms), sponsored by Institute for Respiratory Health. Primary endpoint: Change in syndecan-1. Started Feb 2020; status: recruiting.
02
Drugs
lidocainedoxycycline
03
Conditions
coronary arteriosclerosisCardiac valve disease (VHD)aortopathy
Beyond the preview
Go deeper on ACTRN12619000621112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000621112.